We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

By LabMedica International staff writers
Posted on 24 Feb 2015
Print article
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).
Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.

Saposin C is a multifunctional protein known to activate lysosomal enzymes and induce membrane fusion in an acidic environment. Excessive accumulation of lipid-coupled saposin C in lysosomes is cytotoxic. Because tumors generate an acidic microenvironment, caused by leakage of lysosomal enzymes and hypoxia, it was hypothesized that saposin C may be an effective anticancer agent.

SapC–DOPS nanovesicles had been shown previously to target phosphatidylserine, an anionic phospholipid preferentially exposed in the surface of cancer cells and tumor-associated vasculature. Since binding of SapC to phosphatidylserine is favored at acidic pHs, and the latter characterizes the milieu of many solid tumors, investigators at the University of Cincinnati (OH, USA) and their colleagues at Nanjing Medical University (China) tested the effect of pH on the binding capacity of SapC–DOPS to lung tumor cells and the influence of the nanovesicles on the viability of the cells.

Results published in the February 2015 online edition of the journal Molecular Cancer Therapeutics revealed that, as expected, SapC–DOPS binding to cancer cells was more pronounced under acidic conditions. Viability assays on a panel of human lung tumor cell cultures showed that SapC–DOPS cytotoxicity was positively correlated with cell surface phosphatidylserine levels, whereas mitochondrial membrane potential measurements were consistent with apoptosis-related cell death.

Using a fluorescence tracking method in live mice, the investigators showed that SapC–DOPS specifically targeted human lung cancer xenografts, and that systemic therapy with SapC–DOPS induced tumor apoptosis and significantly inhibited tumor growth without negatively affecting normal tissues.

Senior author Dr. Xiaoyang Qi, professor of hematology-oncology at the University of Cincinnati, said, "Using a double-tracking method in live models, we showed that the nanovesicles were specifically targeted to the tumors. These data suggest that the acidic phospholipid phosphatidylserine is a biomarker for lung cancer, as it has been found to be for pancreatic and brain tumors in previous studies, and can be effectively targeted for therapy using cancer-selective SapC-DOPS nanovesicles. We observed that the nanovesicles selectively killed human lung cancer cells, and the noncancerous, or untransformed cells, remained unaffected. This toxic effect correlated to the surface exposure level of phosphatidylserine on the tumor cells. Our results show that SapC-DOPS could be a promising treatment option for lung cancer worthy of further clinical study."

Related Links:

University of Cincinnati
Nanjing Medical University


New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Unit-Dose Packaging solution
HLX
New
Automated Cell Counter
QuadCount
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.